Privia Health Group, Inc.
PRVA
$23.94
$0.562.40%
| Weiss Ratings | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C | |||
| Rating Factors | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Fair | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.31 | |||
| Price History | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -6.81% | |||
| 30-Day Total Return | 6.21% | |||
| 60-Day Total Return | 14.22% | |||
| 90-Day Total Return | 30.39% | |||
| Year to Date Total Return | 21.89% | |||
| 1-Year Total Return | 17.24% | |||
| 2-Year Total Return | -8.21% | |||
| 3-Year Total Return | 13.08% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -10.21% | |||
| 52-Week Low % Change | 46.86% | |||
| Price | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $26.04 | |||
| 52-Week Low Price | $15.92 | |||
| 52-Week Low Price (Date) | May 21, 2024 | |||
| 52-Week High Price (Date) | Feb 27, 2025 | |||
| Valuation | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.82B | |||
| Enterprise Value | 2.38B | |||
| Price/Earnings (TTM) | 215.48 | |||
| Earnings Per Share (TTM) | 0.11 | |||
| Earnings Per Share Growth | -43.49% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.70 | |||
| Price/Book (Q) | 4.43 | |||
| Enterprise Value/Revenue (TTM) | 1.37 | |||
| Price | $23.94 | |||
| Enterprise Value/EBITDA (TTM) | 98.16 | |||
| Enterprise Value/EBIT | 140.17 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 126.42M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 571 366 8850 | |||
| Address | 950 North Glebe Road Arlington, VA 22203 | |||
| Website | www.priviahealth.com | |||
| Country | United States | |||
| Year Founded | 2007 | |||
| Profitability | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 0.97% | |||
| Profit Margin | 0.82% | |||
| Management Effectiveness | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 0.99% | |||
| Return on Equity | 2.64% | |||
| Income Statement | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.74B | |||
| Total Revenue (TTM) | 1.74B | |||
| Revenue Per Share | $13.73 | |||
| Gross Profit (TTM) | 176.85M | |||
| EBITDA (TTM) | 24.25M | |||
| EBIT (TTM) | 16.98M | |||
| Net Income (TTM) | 14.39M | |||
| Net Income Avl. to Common (TTM) | 14.39M | |||
| Total Revenue Growth (Q YOY) | 4.55% | |||
| Earnings Growth (Q YOY) | 130.94% | |||
| EPS Diluted (TTM) | 0.11 | |||
| EPS Diluted Growth (Q YOY) | 24.58% | |||
| Balance Sheet | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 491.15M | |||
| Cash Per Share (Q) | $3.88 | |||
| Total Current Assets (Q) | 834.82M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 683.45M | |||
| Current Ratio (Q) | 1.859 | |||
| Book Value Per Share (Q) | $5.28 | |||
| Total Assets (Q) | 1.14B | |||
| Total Current Liabilities (Q) | 449.15M | |||
| Total Debt (Q) | 5.59M | |||
| Total Liabilities (Q) | 452.34M | |||
| Total Common Equity (Q) | 635.18M | |||
| Cash Flow | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -11.98M | |||
| Cash from Financing (TTM) | 4.33M | |||
| Net Change in Cash (TTM) | 101.64M | |||
| Levered Free Cash Flow (TTM) | 104.86M | |||
| Cash from Operations (TTM) | 109.28M | |||
